EUCTR2005-000203-34-ES进行中（未招募）不适用
Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks versus 48 weeks of treatment in patients with chronic hepatitis C genotype II and/or III coinfected with human inmunodeficiency virus. - 24 weeks vs. 48 weeks of treatment of coinfected HIV/HCV patients genotype II-III
Enrique Ortega González0 个研究点目标入组 186 人开始时间: 2012年8月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 186
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients in treatment with peginterferon alfa 2a and ribavirin which HCV-RNA is undetectable at 24 weeks- patients with RNA-HCV positive and genotype II-III at 44 weeks before the start of the study- HIV positive- AIDS stable- pregnancy test negative- patient authorization to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 186
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with HCV-RNA positive after 24 weeks of treatment with peginterferon alfa 2a in combination with ribavirin - patients with other different treatment to the study- 3 or more weeks without treatment between the end of the standard treatment and the inclusion of the trial
研究者
相似试验
进行中（未招募）
不适用
Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks more of treatment in patients with chronic hepatitis C genotype 1 and/or 4 co-infected with human inmmunodeficiency virus - Treatment of co-infected HIV/HCV patients genotype 1/4 24 weeks more than standar duratioChronic hepatitis CEUCTR2004-004948-45-ESJosé Hernández-Quero. Hospital Clínico San Cecilio
进行中（未招募）
不适用
Open, multicenter and randomized phase IV trial to evaluate the viral kinetic during 12 first weeks of patients with chronic hepatitis C genotype 1 and 4 coinfected with HIV treated with induction doses of peginterferon alfa 2a (270 mcg/week) and ribavirin (1600 mg/day) with the support of epoetin beta (450 UI/kg/week) - Study of viral kinetic of HCV in HIV patientsChronic hepatitis CEUCTR2004-000907-16-ESBonaventura Clotet/Ramón Planas/Ricard Solá
进行中（未招募）
1 期
A study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in HIV+ patients.EUCTR2019-000199-41-ESFundación SEIMC-GESIDA234
进行中（未招募）
不适用
Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)EUCTR2005-001026-89-DESerono GmbH100
已完成
不适用
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-019-04BRISTOL MYERS SQUIBB COMPANY,